# Supplementary Table S6: Policy Intervention ROI Analysis

## Overview

This table documents the policy intervention framework integrated from the pipeline model (Track A). Each intervention is evaluated for its return on investment (ROI) in terms of acceleration gain per dollar invested.

---

## Policy Interventions

| ID | Intervention | Category | Annual Cost ($M) | Duration (Years) | Total Cost ($B) | ROI (Accel/$B) | Evidence Quality | Primary Domain |
|----|-------------|----------|------------------|------------------|-----------------|----------------|------------------|----------------|
| INF-002 | Autonomous Synthesis Facilities | Infrastructure | 60 | 5 | 0.30 | 0.30 | 4/5 | Materials Science |
| INT-001 | Regulatory Harmonization | International | 60 | 5 | 0.30 | 0.20 | 3/5 | Drug Discovery |
| REG-001 | Adaptive Trial Expansion | Regulatory Reform | 200 | 5 | 1.00 | 0.20 | 4/5 | Drug Discovery |
| REG-002 | Accelerated Approval Expansion | Regulatory Reform | 150 | 5 | 0.75 | 0.15 | 4/5 | Drug Discovery |
| INF-001 | Cryo-EM Infrastructure Expansion | Infrastructure | 100 | 5 | 0.50 | 0.12 | 5/5 | Structural Biology |
| AI-001 | AI Biology Research Doubling | AI Investment | 600 | 5 | 3.00 | 0.10 | 4/5 | All Domains |
| AI-002 | AI Compute Infrastructure | AI Investment | 400 | 5 | 2.00 | 0.08 | 3/5 | Structural Biology |
| INF-003 | Federated Health Data Network | Infrastructure | 300 | 5 | 1.50 | 0.07 | 3/5 | Clinical Genomics |
| WF-001 | AI-Biology Training Programs | Workforce | 100 | 10 | 1.00 | 0.05 | 4/5 | All Domains |
| REG-003 | Real-World Evidence Integration | Regulatory Reform | 400 | 7 | 2.80 | 0.04 | 3/5 | Drug Discovery |

---

## ROI Calculation Methodology

### Formula

```
ROI = Δ_acceleration / (Total_cost / $1B)

where:
  Δ_acceleration = Enhanced_system_accel - Baseline_system_accel
  Total_cost = Annual_cost × Duration_years
```

### Domain Effects

Each intervention affects specific domains with multiplicative effects:

| Intervention | SB | DD | MS | PD | CG |
|-------------|-----|-----|-----|-----|-----|
| Autonomous Synthesis | - | - | 1.35× | - | - |
| Regulatory Harmonization | - | 1.08× | - | - | - |
| Adaptive Trial Expansion | - | 1.15× | - | - | 1.05× |
| Accelerated Approval | - | 1.10× | - | - | - |
| Cryo-EM Infrastructure | 1.20× | - | - | 1.05× | - |
| AI Biology Doubling | 1.10× | 1.08× | 1.08× | 1.12× | 1.10× |
| AI Compute Infrastructure | 1.08× | - | 1.06× | 1.10× | - |
| Federated Health Data | - | 1.08× | - | - | 1.15× |
| Training Programs | 1.05× | 1.05× | - | 1.08× | 1.05× |
| RWE Integration | - | 1.12× | - | - | 1.08× |

---

## Portfolio Analysis

### Optimal $10B Portfolio

Selecting highest-ROI interventions under budget constraint:

| Rank | Intervention | Cost ($B) | Cumulative ($B) | ROI |
|------|-------------|-----------|-----------------|-----|
| 1 | Autonomous Synthesis Facilities | 0.30 | 0.30 | 0.30 |
| 2 | Regulatory Harmonization | 0.30 | 0.60 | 0.20 |
| 3 | Adaptive Trial Expansion | 1.00 | 1.60 | 0.20 |
| 4 | Accelerated Approval Expansion | 0.75 | 2.35 | 0.15 |
| 5 | Cryo-EM Infrastructure | 0.50 | 2.85 | 0.12 |
| 6 | AI Biology Research Doubling | 3.00 | 5.85 | 0.10 |
| 7 | AI Compute Infrastructure | 2.00 | 7.85 | 0.08 |
| 8 | Federated Health Data Network | 1.50 | 9.35 | 0.07 |

**Portfolio Results**:
- Total Investment: $9.35B
- Baseline System Acceleration: 2.83×
- Enhanced System Acceleration: 3.76× (projected)
- Total Acceleration Gain: +0.93×
- Portfolio ROI: 0.10 acceleration/$B

---

## Key Insights

### Highest ROI Interventions

1. **Autonomous Synthesis Facilities** (ROI: 0.30/B)
   - Addresses materials science bottleneck directly
   - A-Lab style facilities dramatically increase synthesis throughput
   - Relatively low cost with high domain-specific impact

2. **Regulatory Reforms** (ROI: 0.15-0.20/B)
   - Adaptive trials and accelerated approval pathways
   - High impact on drug discovery domain
   - Policy changes with moderate implementation costs

3. **Cryo-EM Infrastructure** (ROI: 0.12/B)
   - Enables validation of AI structure predictions
   - Removes structural biology validation bottleneck
   - Strong evidence base from NIH working groups

### Lower ROI but Important

- **AI Investment** (ROI: 0.08-0.10/B): Broad impact but expensive
- **Workforce Training** (ROI: 0.05/B): Long-term benefits, necessary for sustainability

---

## Evidence Sources

| Intervention | Primary Source | Supporting Evidence |
|-------------|----------------|---------------------|
| Autonomous Synthesis | Szymanski et al. 2023 (A-Lab) | GNoME backlog analysis |
| Regulatory Harmonization | ICH guidelines | FDA/EMA cooperation reports |
| Adaptive Trial Expansion | FDA Modernization Act 2.0 | Adaptive trial literature |
| Accelerated Approval | FDA CDER reports | Approval timeline analyses |
| Cryo-EM Infrastructure | NIH cryo-EM working group | Structural biology surveys |
| AI Biology Research | NSF/NIH AI research trends | Industry investment data |
| AI Compute | NAIRR plans | GPU shortage analyses |
| Federated Health Data | NIH data sharing initiatives | Privacy-preserving ML literature |
| Training Programs | NSF CAREER awards | Industry hiring trends |
| RWE Integration | 21st Century Cures Act | RWE guidance documents |

---

## Limitations

1. **ROI Uncertainty**: Calculated effects have wide confidence intervals
2. **Implementation Lag**: Not all interventions take effect immediately
3. **Interaction Effects**: Portfolio effects may not be purely additive
4. **Political Feasibility**: Some interventions face regulatory barriers
5. **Scenario Dependence**: ROI varies across scenarios

---

## Implementation Notes

The PolicyROICalculator class in `enhanced_features.py` implements this framework:

```python
from enhanced_features import PolicyROICalculator, POLICY_INTERVENTIONS

calculator = PolicyROICalculator(model)
results = calculator.rank_interventions(year=2030)
portfolio = calculator.portfolio_analysis(budget_millions=10000)
```

---

*Table S6 completed: January 2026*
*Source: enhanced_features.py PolicyROICalculator module*
